Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy

Sun, Weitong; Wang, Yong; Cai, Mingyue; Li, Lin; Chen, Xiaoyan; Cao, Zhong; Zhu, Kangshun; Shuai, Xintao

doi:10.1039/c7bm00866j

Cited by 46 publications

(23 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sunitinib liposomes were tested, in combination with liposomal irinotecan against a PC12 neuroendocrine tumour [ 197 ] and in combination with vinorelbine liposomes, for the treatment of invasive breast cancer [ 198 ]. Sorafenib was co-encapsulated in liposomes with photocyanine [ 199 ], gadolinium [ 200 ], and siRNA [ 201 ]. Further studies with these formulations may clarify if such strategies have the potential to enhance suppression of tumour neovasculature.…”

Section: Future Directionsmentioning

confidence: 99%

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Gilabert-Oriol¹,

Ryan²,

Leung

et al. 2018

IJMS

View full text Add to dashboard Cite

Tumours are complex systems of genetically diverse malignant cells that proliferate in the presence of a heterogeneous microenvironment consisting of host derived microvasculature, stromal, and immune cells. The components of the tumour microenvironment (TME) communicate with each other and with cancer cells, to regulate cellular processes that can inhibit, as well as enhance, tumour growth. Therapeutic strategies have been developed to modulate the TME and cancer-associated immune response. However, modulating compounds are often insoluble (aqueous solubility of less than 1 mg/mL) and have suboptimal pharmacokinetics that prevent therapeutically relevant drug concentrations from reaching the appropriate sites within the tumour. Nanomedicines and, in particular, liposomal formulations of relevant drug candidates, define clinically meaningful drug delivery systems that have the potential to ensure that the right drug candidate is delivered to the right area within tumours at the right time. Following encapsulation in liposomes, drug candidates often display extended plasma half-lives, higher plasma concentrations and may accumulate directly in the tumour tissue. Liposomes can normalise the tumour blood vessel structure and enhance the immunogenicity of tumour cell death; relatively unrecognised impacts associated with using liposomal formulations. This review describes liposomal formulations that affect components of the TME. A focus is placed on formulations which are approved for use in the clinic. The concept of tumour immunogenicity, and how liposomes may enhance radiation and chemotherapy-induced immunogenic cell death (ICD), is discussed. Liposomes are currently an indispensable tool in the treatment of cancer, and their contribution to cancer therapy may gain even further importance by incorporating modulators of the TME and the cancer-associated immune response.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Gilabert-Oriol¹,

Ryan²,

Leung

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…More recently, Zang and his group demonstrated that co-delivery of VEGF-siRNA and Sorafenib through pH-sensitive liposomes showed a synergistic effect in hepatocellular carcinoma [89]. Several other lipid-based NPs, along with other chemotherapeutics, are also being used for better antiangiogenic and antitumor therapy [90,91]. mTOR inhibitor like rapamycin and its analogs also proved their antiangiogenic capability.…”

Section: Lipid-based Nanoparticles For Antiangiogenic Therapymentioning

confidence: 99%

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer

Mukherjee¹,

Madamsetty

Paul

et al. 2020

IJMS

View full text Add to dashboard Cite

Angiogenesis is a process of generation of de-novo blood vessels from already existing vasculature. It has a crucial role in different physiological process including wound healing, embryonic development, and tumor growth. The methods by which therapeutic drugs inhibit tumor angiogenesis are termed as anti-angiogenesis cancer therapy. Developments of angiogenic inhibiting drugs have various limitations causing a barrier for successful treatment of cancer, where angiogenesis plays an important role. In this context, investigators developed novel strategies using nanotechnological approaches that have demonstrated inherent antiangiogenic properties or used for the delivery of antiangiogenic agents in a targeted manner. In this present article, we decisively highlight the recent developments of various nanoparticles (NPs) including liposomes, lipid NPs, protein NPs, polymer NPs, inorganic NPs, viral and bio-inspired NPs for potential application in antiangiogenic cancer therapy. Additionally, the clinical perspectives, challenges of nanomedicine, and future perspectives are briefly analyzed.

show abstract

“…Small interfering RNA (siRNA) are known to specifically inhibit the expression of target genes without inflicting significant toxicity (Dykxhoorn & Lieberman, 2006 ; Yang & Zhang, 2012 ). Our expectation is that VEGF siRNA will inhibit VEGF expression (Feng et al., 2014 ) and thereby realize anti-angiogenesis in tumors (Sun et al., 2017 ). Therefore, the simultaneous delivery of chemotherapy drugs and VEGF siRNA for cancer therapy is expected to hold particular promise as a potentially useful dual-modality approach for treating highly vascularized tumors such as NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy

et al. 2020

View full text Add to dashboard Cite

The combination of chemotherapeutic drug paclitaxel (PTX) and VEGF siRNA could inhibit cancer development with synergistic efficacy. However, efficient and safe delivery systems with high encapsulation efficiency of PTX and a long-time release of drugs are urgently needed. In this study, novel nanoparticles (PTX/siRNA/FALS) were constructed by using tripeptide lipid (L), sucrose laurate (S), and folate-PEG 2000-DSPE (FA) to co-deliver PTX and siRNA. The cancer cell targeting nanoparticle carrier (PTX/siRNA/FALS) showed anticipated PTX encapsulation efficiency, siRNA retardation ability, improved cell uptake and sustained and controlled drug release. It led to significant anti-tumor activity in vitro and in vivo by efficient inhibition of VEGF expression and induction of cancer cell apoptosis. Importantly, the biocompatibility of the carriers and low dosage of PTX required for effective therapy greatly reduced the toxicity to mice. The targeting nanoparticles show potential as an effective codelivery platform for RNAi and chemotherapy drugs, aiming to improve the efficacy of cancer therapy.

show abstract

Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy

Cited by 46 publications

References 32 publications

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer

Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy

Contact Info

Product

Resources

About